Tuesday, February 17, 2026
ADVT 
International

Protest against Waqf Act will continue, says Congress MLA Arif Masood

Darpan News Desk IANS, 10 Apr, 2025 12:25 PM
  • Protest against Waqf Act will continue, says Congress MLA Arif Masood

Bhopal, April 10 (IANS) Congress MLA Arif Masood, who organised a protest against the Waqf (Amendment) Act in Bhopal on Thursday, reiterated that the Muslim community will never accept this newly enacted law and the protests against it will continue.

Addressing a large gathering of the people from the Muslim community, Masood, who is MLA from Bhopal Madhya assembly seat, said, “All India Muslim Personal Law Board (AIMPLB) has always opposed the Waqf Act and will continue to oppose at each level.”

He further alleged that this law was brought not to protect Waqf, reiterating that the BJP-led government has imposed the Waqf (Amendment) Act forcefully on the Muslim community.

“Protest against this law will continue until the Centre withdraws it,” he claimed.

Notably, after the Waqf (Ammendment) Bill-2025 was passed in both the Houses of the Parliament, President Draupadi Murmu on April 5 gave her assent to it, becoming an Act, which came into effect from April 8.

Over 10 petitions, including those by politicians and the All India Muslim Personal Law Board (AIMPLB) and Jamiat Ulama-i-Hind, were filed in the Supreme Court (SC) to challenge the validity of the new law.

The petitioners have submitted that the provisions of the law discriminated against Muslims by imposing restrictions which were not part of the governance of other religious endowments.

The SC bench headed by Chief Justice of India (CJI) Sanjiv Khanna is scheduled to hear the matter on April 16.

The Centre has already filed a caveat in the apex court to ensure no order is passed without hearing it first.

Responding to Aarif Masood’s statement, BJP MLA and Minister, Wiswas Sarang, said that the large Muslim population has welcomed the Waqf Act.

He said only some Muslim leaders, who have illegally encroached Waqf properties, are opposing it for their personal gain.

MORE International ARTICLES

WATCH: France Alert as Terrorist Strikes Nice Again | "Islamic Terrorism" says President Macron

WATCH: France Alert as Terrorist Strikes Nice Again |
WATCH: A deadly terrorist attack has targeted France. According to Police, three people have been killed in a knife attack at a church in the French city of Nice.

WATCH: France Alert as Terrorist Strikes Nice Again | "Islamic Terrorism" says President Macron

Trump formally lets Canadian aluminum off hook

Trump formally lets Canadian aluminum off hook
The U.S. president formally signed a proclamation today exempting Canadian aluminum exports from punitive Section 232 tariffs.

Trump formally lets Canadian aluminum off hook

Prince Harry says ignorance no excuse for unconscious bias

Prince Harry says ignorance no excuse for unconscious bias
Harry talked about racial inequality and social justice in a video discussion with the Black Lives Matter activist Patrick Hutchinson as part of the GQ Heroes Conference, which is being broadcast this week.

Prince Harry says ignorance no excuse for unconscious bias

Halloween goes on at the White House with a few twists

Halloween goes on at the White House with a few twists
In years past, the president and first lady personally handed out candy to the costume-clad kids. This year, the treats were provided separately as participants walked along a path on the South Lawn.

Halloween goes on at the White House with a few twists

AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca resuming US testing of COVID-19 vaccine
The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

AstraZeneca resuming US testing of COVID-19 vaccine

FDA approves first COVID-19 drug: antiviral remdesivir

FDA approves first COVID-19 drug: antiviral remdesivir
The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

FDA approves first COVID-19 drug: antiviral remdesivir